<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509570</url>
  </required_header>
  <id_info>
    <org_study_id>3-2018-0302</org_study_id>
    <nct_id>NCT04509570</nct_id>
  </id_info>
  <brief_title>A Prospective &amp; Retrospective Study on Ectopic Lymphoid-like Structures in Chronic Skins of Autoimmune Bullous Diseases</brief_title>
  <official_title>A Prospective &amp; Retrospective Study on the Presence of Ectopic Lymphoid-like Structures and Intralesional Steroid Injection for the Chronic Skin Lesion of Autoimmune Bullous Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the presence or absence of ectopic lymph node-like&#xD;
      structures in skin lesions of patients with autoimmune bullous disease and the subtypes of&#xD;
      the cells deposited there. In addition, this study clarifies the therapeutic effect of&#xD;
      intralesional steroid injection in patients with pemphigus harboring ectopic lymph node-like&#xD;
      structure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">December 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome: size of lesions</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The area of the lesions will be measured using the Image J program</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The presence or absence of ectopic-lymph node-like structure by histologic evaluation</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The presence of absence of ectopic-lymph node-like structure will be evaluated by histologic evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autoimmune Bullous Disease</condition>
  <arm_group>
    <arm_group_label>Treatment: ILI(Intralesional injection)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>5~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared</description>
    <arm_group_label>Treatment: ILI(Intralesional injection)</arm_group_label>
    <other_name>Steroid injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        &lt;Presence of Ectopic Lymphoid-like Structures in the Skin lesion of Autoimmune Bullous&#xD;
        Disease Patients&gt;&#xD;
&#xD;
        Prospective study Inclusion Criteria:&#xD;
&#xD;
          1. Adults over 19&#xD;
&#xD;
          2. Patietns who voluntarily signed the consent form&#xD;
&#xD;
          3. Patients who are diagnosed with autoimmune bullous disease through clinical,&#xD;
             histological and serological tests&#xD;
&#xD;
        Retrospective study Inclusion Criteria:&#xD;
&#xD;
          1. Samples in human-derived banks from March 2013 to October 2018&#xD;
&#xD;
          2. Patients who are diagnosed with autoimmune bullous disease through clinical,&#xD;
             histological and serological tests&#xD;
&#xD;
          3. Adults over 19 &lt;Treatment of Ectopic Lymphoid-like Structures in the Skin lesion of&#xD;
             Autoimmune Bullous Disease Patients&gt;&#xD;
&#xD;
        Prospective study Inclusion Criteria:&#xD;
&#xD;
          1. Adults over 19&#xD;
&#xD;
          2. Patients who voluntarily signed the consent form&#xD;
&#xD;
          3. Patients who have skin lesions harboring ectopic lymph node-like structure in a&#xD;
             prospective or retrospective manner&#xD;
&#xD;
          4. Patients who have chronic lesions sustained for more than 4 months during the&#xD;
             treatment of systemic corticosteroids&#xD;
&#xD;
        Retrospective study Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have skin lesions harboring ectopic lymph node-like structure in a&#xD;
             retrospective manner&#xD;
&#xD;
          2. Paitents who have been treated for intralesional steroid injection&#xD;
&#xD;
          3. Patients who have data of photography to compare the clinical effects before and after&#xD;
             intralesional corticosteroid treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients who do not meet the criteria for autoimmune bullous disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong Hoon Kim</last_name>
    <phone>82-2-2019-4601</phone>
    <email>jhkim074@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>GangnamSeverance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JongHoon Kim</last_name>
      <phone>82-2-2019-4601</phone>
      <email>jhkim074@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Jong Hoon Kim, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ELS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tertiary Lymphoid Structures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

